Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06708299 · ClinicalTrials.gov registry record · Phase 3

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

A Phase 3 study of Recurrent Pericarditis, sponsored by Cardiol Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
110
Enrollment target
20
Study locations

NCT06708299 is a Phase 3 study of Recurrent Pericarditis that is actively recruiting participants, run by Cardiol Therapeutics. The registered enrollment target is 110 participants, below the 199-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06708299, a Phase 3 study of Recurrent Pericarditis, is actively recruiting participants, sponsored by Cardiol Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
110 participants
Enrollment target
20
Study locations

Study Summary

Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.

Conditions Studied

Recurrent Pericarditis

Interventions

  • DRUG CardiolRx

Study Locations (20)

New York

  • NYU Langone Health - New York
  • Columbia University - New York Presbyterian - New York
  • Columbia University - New York Presbyterian - New York
  • Lenox Hill Hospital - New York

Florida

  • Mayo Clinic Florida - Jacksonville
  • Mayo Clinic - Jacksonville

Maryland

  • Johns Hopkins University - Baltimore
  • MedStar Health Institute - Columbia

Minnesota

  • Minneapolis Heart Institute - Minneapolis
  • Mayo Clinic - Rochester

Virginia

  • University of Virginia - Charlottesville
  • Virginia Commonwealth University - Richmond

Arizona

  • Mayo Clionic Arizona - Phoenix

California

  • UCI Health - Irvine

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2025-04-07
Est. Completion 2026-10-21
Phase Phase 3

Sponsor

Cardiol Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06708299

The ClinicalTrials.gov registry entry for NCT06708299 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (45% lower). The listed sponsor is Cardiol Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Pericarditis appearing as the primary indexed condition, and to 1 intervention - of which CardiolRx is the first listed.

NCT06708299 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT06708299 about?

NCT06708299 is a clinical study titled "CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)". Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment ...

What is the current status of trial NCT06708299?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2025-04-07. Estimated completion is 2026-10-21.

What conditions does trial NCT06708299 study?

This clinical trial studies the following conditions: Recurrent Pericarditis.

What interventions are being tested in trial NCT06708299?

The interventions under investigation include: CardiolRx (DRUG).

Who is sponsoring clinical trial NCT06708299?

This trial is sponsored by Cardiol Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06708299 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Pericarditis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Pericarditis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.